ESR1 and ovarian cancer: The same signature was highly enriched when ES-2 was compared against all other ovarian cancer cell lines and SAS against all other head and neck cell lines, while expression of prototypic tissue-specific oncogenic signatures, such as estrogen receptor signaling in ovary, were depleted (Supplementary Fig. 6e).